XML 42 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1
Net Product Sales (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Dec. 31, 2016
Revenue Disclosure [Line Items]        
Net product sales $ 987,909 $ 858,245    
Activity of Sales Related Deductions [Roll Forward]        
Balance 109,319 56,033 $ 85,302 $ 45,851
Provision related to current period sales 111,381 89,603    
Credits/payments (87,364) (79,421)    
Rebates and Chargebacks        
Activity of Sales Related Deductions [Roll Forward]        
Balance 47,661 23,118 29,840 12,712
Provision related to current period sales 48,495 38,908    
Credits/payments (30,674) (28,502)    
Distribution Related Fees        
Activity of Sales Related Deductions [Roll Forward]        
Balance 43,833 28,353 34,142 29,465
Provision related to current period sales 51,716 41,175    
Credits/payments (42,025) (42,287)    
Other Sales Related Deductions        
Activity of Sales Related Deductions [Roll Forward]        
Balance 17,825 4,562 $ 21,320 $ 3,674
Provision related to current period sales 11,170 9,520    
Credits/payments $ (14,665) $ (8,632)    
Besse Medical [Member] | Customer concentration risk | Gross Sales Revenue        
Risks and Uncertainties [Abstract]        
Concentration risk, percentage 55.00% 53.00%    
EYLEA        
Revenue Disclosure [Line Items]        
Net product sales $ 984,049 $ 854,387    
ARCALYST        
Revenue Disclosure [Line Items]        
Net product sales $ 3,860 $ 3,858    
McKesson Corporation [Member] | Customer concentration risk | Gross Sales Revenue        
Risks and Uncertainties [Abstract]        
Concentration risk, percentage 40.00% 27.00%    
Curascript SD [Member] | Customer concentration risk | Gross Sales Revenue        
Risks and Uncertainties [Abstract]        
Concentration risk, percentage   19.00%    
Minimum [Member] | Customer concentration risk | Gross Sales Revenue        
Risks and Uncertainties [Abstract]        
Concentration risk, percentage 10.00% 10.00%